MetrioPharm's studies confirm very good safety profile for lead compound to combat chronic inflammatory diseases

MetrioPharm AG, a pharmaceutical company developing drugs for chronic inflammatory diseases, reports positive results from two long-term preclinical toxicology studies in the rat and the dog. They respectively lasted six and 12 months. The results confirm the very good safety profile of MetrioPharm's lead compound MP1032. They allow for long-term clinical studies in chronic indications to be conducted in the future. The positive completion of the long-term toxicology studies therefore signifies an important milestone in the development program of MP1032.

In each of the two trials, different doses (low-dose, mid-dose, high-dose) of MP1032 were administered orally to four experimental groups, including a control group. In the rat, two doses per 100 mg/kg body weight, 500 mg/kg body weight and 1000 mg/kg body weight, were administered per day. Analogically, the doses in the dog were 25mg/kg, 50 mg/kg and 125 mg/kg. All animals in both experimental batches were examined daily during the study for toxicological side effects. Simultaneously macroscopic and histopathological analyses were conducted. Their results confirmed the excellent safety profile of MP1032. Very good tolerability of the compound was observed with respect to all factors investigated.

Dr. Wolfgang Brysch, CEO of MetrioPharm AG, commented: "These results are another significant stride for us. We can now explore long-term administration of MP1032 in humans. This opens up further essential opportunities for the company to advance our innovative compound MP1032 in a sustainable and all-encompassing way to combat chronic inflammatory diseases."